What Is the Best Probiotic to Take With C. diff?

Saccharomyces boulardii, a medicinal yeast, has the strongest clinical evidence of any probiotic studied alongside standard C. diff treatment, particularly for preventing recurrence. That said, major gastroenterology guidelines still stop short of recommending any probiotic for C. difficile infection, and the gap between what individual trials show and what expert panels endorse is wider than you might expect. The answer depends heavily on your specific situation, the timing of when you start, and whether you’re dealing with a first episode or a stubborn recurrence.

Why Guidelines Do Not Recommend Probiotics for C. diff

If you search for probiotic advice on C. diff, you’ll quickly run into a contradiction: individual trials look promising, but the American Gastroenterological Association’s clinical practice update states that probiotics are not advised to prevent an initial or recurrent C. difficile infection.¹ That position isn’t because every trial failed. It reflects the fact that existing trials vary in quality, use different probiotic strains at different doses, and don’t yet provide the consistent large-scale evidence that guideline committees require before making a blanket recommendation. For clinicians, “not advised” doesn’t necessarily mean “proven useless.” It means the evidence hasn’t crossed the threshold where they feel comfortable telling every patient to take one. Your own doctor may still suggest a probiotic based on the strain-specific data below, especially if you’re dealing with recurrent infection.

Saccharomyces boulardii Has the Strongest Track Record

S. boulardii is a non-pathogenic yeast, not a bacterium, and that distinction matters. Because it’s a yeast, it isn’t killed by the antibiotics used to treat C. diff, which means it can keep working while vancomycin or fidaxomicin clear the infection. It’s the most studied probiotic in the context of C. difficile by a wide margin.

A randomized controlled trial comparing vancomycin alone to vancomycin plus S. boulardii found a recurrence rate of roughly 2% in the combination group versus about 13% with vancomycin alone.² Earlier work found similar patterns. In patients with a history of recurrent C. diff who received antibiotics plus S. boulardii, recurrence dropped to about 35% compared with 65% in those on antibiotics alone.³ A systematic review of the S. boulardii literature confirmed that in two trials looking at recurrence prevention, one showed a clear reduction in relapse and another showed a strong trend toward reduction in patients on high-dose vancomycin.⁴

The effect is most consistent in people who have already had at least one recurrence. For a first episode of C. diff, the evidence is thinner and less convincing. If you’re weighing whether to add S. boulardii, the case is strongest when your concern is “I keep getting this back.”

Lactobacillus rhamnosus GG and Combination Strains

Lactobacillus rhamnosus GG (often sold as “LGG”) is the other probiotic that regularly appears in C. diff research. Case series and smaller studies have generally shown favorable results with LGG, though the evidence base is not as deep as what exists for S. boulardii.⁵ One trial in hospitalized patients on antibiotics tested a combination of Lactobacillus reuteri and LGG together. In the control group, about 11% developed C. diff infection, while none in the probiotic group did.⁶ That’s a striking result, though it comes from a single trial with a relatively small sample.

There’s also reason to think that multi-strain formulations may outperform single strains in some situations. Lab research has found that multi-species probiotic mixtures showed greater pathogen inhibition than individual component strains in half the comparisons tested, suggesting that combining strains with different mechanisms of action could produce broader coverage against gut pathogens.⁷ A small pilot trial of a four-strain capsule containing Lactobacillus acidophilus, Lactobacillus paracasei, and two Bifidobacterium lactis strains found that patients with mild to moderate C. diff had a shorter duration of diarrhea compared to placebo, though the trial only included 33 people and would need replication.⁸

Clostridium butyricum, a Less Familiar Contender

Outside of North America and Europe, Clostridium butyricum MIYAIRI 588 (CBM 588) is used clinically in Japan and parts of Asia. It’s a spore-forming bacterium that produces large amounts of butyrate, a short-chain fatty acid that feeds the cells lining your colon and supports immune function. In animal studies, CBM 588 significantly improved C. diff symptoms and boosted immune cells in the colon during early infection, including neutrophils and immune-signaling pathways that help clear the bacteria.⁹ When combined with fidaxomicin in mice, CBM 588 lowered C. diff counts in stool, reduced gut permeability, and dampened inflammation more effectively than the antibiotic alone.¹⁰

In a clinical study of 99 patients with mild to moderate C. diff, the success rate of C. butyricum alone was comparable to metronidazole alone, and patients on C. butyricum tended to have shorter bouts of diarrhea, though the difference didn’t reach statistical significance.¹¹ CBM 588 is not widely available in U.S. pharmacies, but it’s gaining attention in the research community and could become a more prominent option in the coming years.

How Probiotics Fight C. diff at a Biological Level

Probiotics don’t all work the same way against C. diff. Some produce antimicrobial compounds that directly inhibit the bacterium. Lactobacillus reuteri, for instance, converts glycerol into reuterin, a compound with demonstrated activity against C. diff and other gut pathogens.¹² Others work indirectly by producing metabolites that change the gut environment. Research on Parabacteroides distasonis, a commensal gut bacterium, showed that when it was co-cultured with a bile acid, it produced deoxycholic acid, which inhibited C. diff growth, toxin production, and spore formation.¹³

Still others bolster the immune system’s response. The butyrate produced by C. butyricum, for example, doesn’t just feed colon cells. It ramps up immune signaling pathways that help the body clear the infection on its own. The variety of mechanisms is part of why multi-strain formulations are interesting, at least in theory: different strains could attack the problem from multiple angles simultaneously.

Timing May Matter as Much as the Strain You Choose

One of the most practical findings in the probiotic-C. diff literature is about when you start taking the probiotic, not just which one. A meta-analysis of hospitalized adults found that probiotics given within two days of the first antibiotic dose were far more effective at preventing C. diff than those started later. Starting early reduced C. diff risk by roughly 68%, while later administration showed no statistically significant benefit at all.¹⁴ Each day of delay chipped away at the probiotic’s effectiveness. If you’re going to use a probiotic alongside antibiotics, earlier is meaningfully better than later.

This finding also helps explain why some trials show disappointing results. If patients in a study started probiotics several days into their antibiotic course, the probiotic may simply have been too late to establish itself in the disrupted gut environment. Timing is an underappreciated variable that can make the same strain look effective in one trial and useless in another.

When Probiotics Become Dangerous

For most people, probiotics are well tolerated. But in critically ill patients, particularly those in the ICU with central venous catheters, the risk calculus changes dramatically. In a cohort of over 23,000 ICU patients who received probiotics, about 86 developed bloodstream infections caused by the probiotic organisms themselves. Patients who developed these infections had more than double the odds of dying compared to those who didn’t. Powder formulations caused infections roughly twice as often as non-powder formulations, likely because of airborne contamination of catheter sites during preparation.¹⁵

S. boulardii deserves particular caution in immunocompromised or critically ill patients. Because it’s a yeast closely related to Saccharomyces cerevisiae, it can cause fungemia, a yeast infection of the blood, if it crosses from the gut into the bloodstream. Case reports have documented central line infections caused by S. cerevisiae in patients with C. diff colitis who were receiving S. boulardii probiotics.¹⁶ Proposed mechanisms include the yeast crossing through a damaged gut wall and contamination of catheters during handling of the probiotic.¹⁷ If you have a central line, are immunocompromised, or are in an ICU, the risks of yeast-based probiotics likely outweigh the benefits.

The Supplement Quality Problem

Even if you choose the right strain, you may not be getting what the label promises. An assessment of commercial probiotic products found that only about a quarter of products listing specific viable organism counts actually met or exceeded their label claims. Nearly a third had misspelled organism names on the label, and viable bacterial counts ranged from zero to two billion colony-forming units per gram, even among products making similar claims.¹⁸ Probiotics are regulated as dietary supplements in the U.S., not as drugs, so manufacturers don’t have to prove that what’s in the bottle matches the label before selling it. If you’re taking a probiotic specifically for C. diff, this isn’t a minor issue. A product containing dead organisms or the wrong strain is just an expensive placebo.

Practical advice here: look for products that list specific strains (not just genus and species), carry third-party verification seals, and store them according to label instructions. Some probiotic organisms are shelf-stable as spores, while others need refrigeration to survive. S. boulardii, being a yeast, tends to be more shelf-stable than many bacterial probiotics, which is one practical advantage.

FDA-Approved Microbiota Therapies for Recurrent C. diff

If you’re dealing with recurrent C. diff, the landscape has shifted substantially. The FDA has approved two live biotherapeutic products specifically for preventing recurrence after standard antibiotic treatment: fecal microbiota live-jslm (brand name Rebyota) and fecal microbiota spores live-brpk (brand name Vowst). These aren’t traditional probiotics. They’re derived from screened donor stool and contain complex communities of microorganisms designed to rebuild the gut ecosystem that C. diff has disrupted.¹⁹

In clinical trials, about 71% of patients treated with Rebyota remained free of C. diff recurrence through eight weeks, compared to 58% on placebo. Vowst showed an even wider gap: recurrence occurred in about 12% of treated patients versus 40% on placebo.²⁰ Vowst is an oral capsule, which makes it more convenient than Rebyota, which is administered rectally. A phase III trial confirmed that Vowst significantly reduced recurrence risk at eight weeks with a durable response through six months.²¹

These products represent a fundamentally different approach from single-strain probiotics. Rather than adding one or two organisms to a damaged ecosystem, they transplant a whole microbial community. For recurrent C. diff that hasn’t responded to repeated antibiotic courses, they’re the strongest clinical tool currently available.

Probiotics May Slow Your Gut’s Natural Recovery

Here’s a finding that complicates the picture in a way most probiotic advocates don’t mention. A study published in Cell found that after antibiotic treatment, people who took a standard multi-strain probiotic experienced a markedly delayed recovery of their native gut microbiome compared to those who recovered spontaneously. The probiotic colonized the gut effectively, but in doing so, it appeared to crowd out the return of the person’s own bacteria. Meanwhile, patients who received a transplant of their own pre-antibiotic stool saw near-complete microbiome recovery within days.²²

This doesn’t mean probiotics are net-harmful for C. diff patients. It does mean there may be a trade-off: the probiotic might help fend off C. diff in the short term while slowing the broader ecosystem repair that provides long-term colonization resistance. The practical implications are still being worked out, but it’s worth knowing that “more probiotics for longer” isn’t necessarily better. A targeted course alongside your antibiotic treatment, rather than months of continuous supplementation afterward, may make more sense given this data.

Cost-Effectiveness in Hospital Settings

Hospitals have been running the numbers on routine probiotic use for patients on antibiotics, and the economics generally favor it, at least in higher-risk groups. A cost-effectiveness analysis found that giving probiotics to hospitalized adults on antibiotics was both cheaper and produced better health outcomes overall. The model predicted about 15 C. diff cases per 1,000 patients with probiotics versus 29 per 1,000 without, with a net cost savings of about $840 per case averted. The benefit was strongest in patients 85 and older, while it wasn’t cost-effective for younger adults aged 18 to 64.²³ A separate analysis in hospitalized children and adolescents also found probiotics to be a cost-saving strategy for preventing C. diff-associated diarrhea.²⁴

These economic findings help explain why some hospitals include probiotics in their antibiotic stewardship protocols even though guidelines don’t formally recommend them. The cost is low, the signal of benefit is real even if imperfect, and the downside in non-ICU patients is minimal.

Emerging Research and Next-Generation Approaches

The field is moving beyond off-the-shelf supplements. Researchers are developing engineered delivery systems that protect probiotic organisms through the harsh stomach environment and release them specifically in the inflamed colon, where they’re needed most. One experimental platform encapsulates Bifidobacterium adolescentis in a hydrogel paired with anti-toxin nanoparticles, with the goal of simultaneously delivering the probiotic and neutralizing C. diff toxins at the site of infection. In mouse models, the combination reduced inflammation, promoted intestinal repair, and restored healthy microbial balance.²⁵ This kind of work is still in early-stage animal research, but it illustrates where the science is heading: away from generic probiotic supplements and toward precision-delivered live therapeutics tailored to specific infections.

A Cochrane review pooling data across adults and children confirmed that the overall signal for probiotic prevention of C. diff-associated diarrhea was consistent regardless of whether the trials enrolled adults or children, inpatients or outpatients, and across different probiotic species and doses.²⁶ The consistency across subgroups is reassuring, even as the overall evidence remains below the threshold that guideline panels demand for a universal recommendation. The tension between “this looks like it works” in trials and “we can’t recommend it for everyone” in guidelines is the defining feature of this topic right now, and it’s likely to persist until larger, more standardized trials settle the question.